Crescent Biopharma CBIO
NASDAQ CBIO
$14.59 -0.17 (-1.15%)
At close: Sep 30, 2026 · 4:00 PM EDT

Crescent Biopharma (CBIO) Change in Receivables (2026)

Updated

Crescent Biopharma's Change in Receivables was -$18 million in Q1 2026.

Analysis

Crescent Biopharma (CBIO) Change in Receivables (2026) Analysis & Trends

For FY2025, Change in Receivables at Crescent Biopharma came in at $18 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change Receivables (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 1.35 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 1.37 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 1.09 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 333.00 Mn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 140.20 Mn
10 Crescent Biopharma 404.96 Mn -302.33 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 -18.00 Mn
API Access

Crescent Biopharma Change in Receivables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=change-in-receivables&ticker=CBIO&period=max&api_key=YOUR_API_KEY